Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Functional multiomics of cellular therapy and immune checkpoint blockade therapy for solid tumors

ABSTRACT: Functional multiomics of cellular therapy and immune checkpoint blockade therapy for solid tumors

PROVIDER: PRJNA796418 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Functional multiomics of cellular therapy and immune checkpoint blockade therapy for solid tumors

Project description:Functional multiomics of cellular therapy and immune checkpoint blockade therapy for solid tumors

| PRJNA796389 | ENA

Resistance to Checkpoint Blockade Therapy Through Inactivation of Antigen Presentation

Project description:Resistance to Checkpoint Blockade Therapy Through Inactivation of Antigen Presentation

| PRJNA398303 | ENA

Molecular portraits of tumor mutational and micro-environmental sculpting by immune checkpoint blockade therapy

Project description:Immune checkpoint blockade (ICB) has demonstrated significant promise for the treatment of advanced malignancies. Anti-CTLA4 and ant-PD1 therapy can activate the immune system and result in durable control in diseases such as melanoma and non-small cell lung cancer.

2018-01-23 | GSE91061 | GEO

Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade

Project description:We previously developed human CAR macrophages (CAR-M) and demonstrated redirection of macrophage anti-tumor function leading to tumor control in immunodeficient xenograft models. Here, we developed clinically relevant fully immunocompetent syngeneic models to evaluate the potential for CAR-M to remodel the tumor microenvironment (TME), induce T cell anti-tumor immunity, and sensitize solid tumors to PD1/PDL1 checkpoint inhibition. In vivo, anti-HER2 CAR-M significantly reduced tumor burden, prolonged survival, remodeled the TME, increased intratumoral T cell and natural killer (NK) cell infiltration, and induced epitope spreading. CAR-M therapy protected against antigen-negative relapse in a T cell dependent fashion, confirming long-term anti-tumor immunity. In HER2+ solid tumors resistant to anti-PD1(aPD1) monotherapy, the combination of CAR-M and aPD1 significantly improved tumor growth control, survival, and remodeling of the TME. These results demonstrate synergy between CAR-M and T cell checkpoint blockade and provide a strategy to enhance response to aPD1 therapy for patients with non-responsive tumors.

2024-11-20 | GSE275417 | GEO

Genomic Correlates of Response and Resistance to Immune Checkpoint Blockade in Solid Tumors

Project description:Genomic Correlates of Response and Resistance to Immune Checkpoint Blockade in Solid Tumors

| PRJNA445758 | ENA

Genomic Correlates of Response and Resistance to Immune Checkpoint Blockade in Solid Tumors

Project description:Genomic Correlates of Response and Resistance to Immune Checkpoint Blockade in Solid Tumors

| PRJNA445759 | ENA

Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade [TCR-Seq]

2024-12-22 | GSE285188 | GEO

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

Project description:Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

| PRJNA476140 | ENA

RNA-seq analysis of isogenic mouse prostate cancer cell lines with distinct sensitivity to immune checkpoint therapy

Project description:Resistant to immune checkpoint blockade (ICB) therapy, especially in a few solid tumor types including advanced prostate cancer (PCa), represents a formidable clinical challenge. In this study, we developed a series of ICB-resistant PCa cell lines from an ICB-sensitive PCa cell line previously developed from the PB-Cre+ PtenL/L p53L/L Smad4L/L mouse model of metastatic PCa. These four cell lines were profiled with RNAseq.

2024-02-13 | GSE252986 | GEO

GutMicrobiota as Biomarker for Immune Checkpoint Blockade Therapy

Project description:Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

| PRJEB48780 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data